- Home
- WING vs TNGX Comparison
WING vs TNGX Comparison
Compare WING & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WING | TNGX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.1B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WING | TNGX |
|---|---|---|
| Price | $109.92 | $25.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 27 | 10 |
| Target Price | ★ $295.92 | $21.78 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 67.84 | 26.89 |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $696,853,000.00 | $62,384,000.00 |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $15.86 | N/A |
| P/E Ratio | $50.33 | ★ N/A |
| Revenue Growth | 11.35 | ★ 48.29 |
| 52 Week Low | $110.44 | $6.25 |
| 52 Week High | $330.42 | $34.39 |
Technical Indicators
Market Signals| Indicator | WING | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 45.73 |
| Support Level | N/A | $25.33 |
| Resistance Level | $126.24 | $25.76 |
| Average True Range (ATR) | 6.08 | 1.38 |
| MACD | 0.38 | -0.00 |
| Stochastic Oscillator | 8.89 | 48.89 |
Price Performance
Historical ComparisonAbout WING Wingstop Inc.
Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across 12 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 units, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.